title: Management of sulfonylurea ingestions.
abstract: In the majority of pediatric patients with an unintentional ingestion of a sulfonylurea, observation and, if necessary, intravenous glucose supplementation, are sufficient. However, with cases of persistent hypoglycemia or cases refractory to IV glucose supplementation, attempts to inhibit insulin secretion should be considered. Octreotide appears effective and safe. It may eliminate the need for prolonged infusions of hypertonic dextrose solutions and secondarily the risks associated with central line access. It has been successful in restoring euglycemia in cases refractory to glucose infusions. In the absence of octreotide, diazoxide remains a viable alternative to decrease insulin secretion.
authors.affiliation: Kentucky Regional Poison Center, Louisville 40232-5070, USA.
authors.forename: H A
authors.initials: HA
authors.lastname: Spiller
mesh_terms: D000931:Antidotes / Q000627:therapeutic use*; D002648:Child; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D003981:Diazoxide / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D005947:Glucose / Q000627:therapeutic use; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000188:drug therapy; D015282:Octreotide / Q000627:therapeutic use; D011041:Poisoning / Q000188:drug therapy / Q000628:therapy; D013453:Sulfonylurea Compounds / Q000378:metabolism / Q000494:pharmacology / Q000506:poisoning*; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000931:Antidotes; D005765:Gastrointestinal Agents; D013453:Sulfonylurea Compounds; D014665:Vasodilator Agents; D005947:Glucose; D003981:Diazoxide; D015282:Octreotide